跳至主要内容
临床试验/CTRI/2021/06/034219
CTRI/2021/06/034219已完成未知

Comparative study between intralesional Measles-Rubella (MR) vaccine versus Purified Protein Derivative(PPD) in treatment of cutaneous warts

Dr Manish Kumar0 个研究点目标入组 100 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • a. Patients with recalcitrant or recurrent or multiple or resistant to treat cutaneous warts.
  • b. Patients, where first and second line of treatment have produced no effect.
  • c. Patient of both sexes aged more than 12 years and less than 70 years.
  • d. No concurrent treatment for cutaneous wart

排除标准

  • a. Patients with fever or signs of any inflammation or infection
  • b. Patient of both sexes aged less than 12 years and more than70 years
  • c. Pregnancy or planning to conceive.
  • d. Lactation
  • e. Immunosuppression or immunosuppressive disease.
  • f. Ano-genital/ Facial warts.
  • g. Past history of asthma, allergic skin disorders, meningitis, convulsions, hypersensitivity to any antigens.

研究者

发起方
Dr Manish Kumar

相似试验